Virginiamycin and sodium monensin supplementation for beef cattle on pasture / Suplementação com virginiamicina e monensina sódica para bovinos de corte a pasto

The aim of this paper was to evaluate the effects of including virginiamycin (VM), sodium monensin (MON) or the association (VM+MON) in the energetic mineral supplement, on the intake and performance of beef cattle on pasture. Forty Nellore heifers with 24 months of age and initial body weight (BW) of 251.5±16.6kg, were distributed in four treatments in a randomized block design. Treatments consisted of adding VM, MON or VM+MON to the supplement (CONT). Additive concentrations were defined to reach a dose of 40 to 45mg/100kg BW. The herbage allowance was not a limiting factor for the animals' intake. Supplement intake was lower than expected, with 33.0, 18.8 and 26.3mg per 100kg BW for VM, MON and VM+MON, respectively. Dry matter intake (DMI, mean=2.65% BW) and animal performance were not affected by the inclusion of additives. The average daily gain (ADG) was 0.561kg/animal day-1. The inclusion of additives in energetic mineral supplement does not affect the DMI and the ADG of grazing animals. The variability in supplement intake and daily dose intake of additives may have influenced the performance of the animals. Monensin inclusion presented the less expensive supplementation cost, due to reduction in supplement intake without changing weight gain.(AU)

Objetivou-se avaliar o efeito da inclusão dos aditivos virginiamicina (VM), monensina sódica (MON) e associação (VM+MON) no suplemento energético-mineral sobre o consumo e desempenho de bovinos manejados em pastagem de Urochloa Brizantha cv. Marandu. Foram utilizadas 40 novilhas Nelore com 24 meses de idade e peso corporal (PC) inicial médio de 251,5+16,6kg distribuídas em delineamento em blocos ao acaso com quatro tratamentos. Os tratamentos consistiam de suplemento energético-mineral (CONT) acrescido de VM, MON ou VM+MON. A oferta de forragem não limitou o consumo dos animais. O consumo dos aditivos foi de 0; 33,0; 18,8 e 26,3mg por 100kg de PC para CONT, VM, MON e VM+MON, respectivamente. O consumo de matéria seca e o desempenho dos animais não foram afetados pela inclusão dos aditivos. O ganho médio diário dos animais foi de 0,561kg dia -1 , sem diferença entre os tratamentos. A inclusão de aditivos no suplemento energético-mineral não alterou o CMS e o desempenho dos animais em pastejo. A variabilidade no consumo de suplemento e na dose ingerida dos aditivos pode ter influenciado o desempenho dos animais.(AU)

Hemangioendotelioma hepático infantil. Un caso multifocal y bilobular, asintomático, con regresión espontánea / Infantile hepatic hemangioendothelioma. A multifocal, bilobular and asymptomatic case with spontaneous regression

El hemangioendotelioma hepático infantil (HHI) es una enfermedad grave y con elevada mortalidad. A pesar de ello, estas lesiones vasculares pueden evolucionar espontáneamente para su resolución completa entre 12 y 18 meses. La decisión de intentar un tratamiento específico y la elección entre las varias opciones terapéuticas continúa siendo polémica, especialmente en los casos asintomáticos de afectación multifocal o bilobular. Describimos un caso de HHI, multifocal y bilobular, asintomático, no sometido a ningún tipo de terapia y con regresión de las lesiones antes de los 2 años de edad (AU)

Infantile hepatic hemangioendothelioma is a severe disease with a high mortality rate. Nevertheless these vascular lesions may experience spontaneous regression within 12 to 18 months. The decision of trying a specific treatment and the choice among the several therapeutic options remains controversial, particularly in those asymptomatic cases of multifocal, bilobular involvement. We describe a case of multifocal, bilobular and asymptomatic infantile hepatic hemangioendothelioma, untreated, and with spontaneous regression before 2 years of age (AU)

Tratamiento adyuvante con oxígeno hiperbárico en un paciente con mucormicosis rino-sinuso-orbitaria. / [Adjunctive treatment with hyperbaric oxygen in a patient with rhino-sinuso-orbital mucormycosis]

Mucormycosis (phycomycosis) is an acute and often fatal infection, mostly seen in diabetics and immunocompromised patients, and seldom in healthy people. Therapy includes aggressive surgical debridement, amphotericin B and control of underlying predisposing condition (diabetes, immunosuppression or immunodeficiency). The rhino-sinuso-orbital presentation is typically observed in insulin-dependent diabetes mellitus with ketoacidosis. This metabolic condition may impair the polymorphonuclear function in a reversible way and this may favour infection by a mucoral. These spores germinate into hyphae, which invade local arteries and arterioles, causing thrombosis, vascular insufficiency and tissue hypoxia and acidosis, conditions which further enhance fungal growth. Hyperbaric oxygen has theoretical value in treating mucormycosis, since it reduces tissue hypoxia caused by the vascular insufficiency. We report an insulin-dependent diabetic patient with rhino-sinuso-orbital mucormycosis, who after being treated with amphotericin B and surgical debridement on two occasions, maintained clinical and tomographic evidence of active infection, and mucoral persistence in the lesion. An aggressive surgical debridement, using microsurgical techniques, was performed. Amphotericin B was increased up to a total dose of 3900 mg. (he had previously received 2900 mg) and hyperbaric oxygen was added as adjunctive treatment. The outcome was successful. There was no evidence of relapse after a 16-month follow-up. This observation would confirm the usefulness of hyperbaric oxygen as adjunctive therapy in mucormycosis.

Tratamiento adyuvante con oxigeno hiperbarico en un paciente con mucormicosis rino-sinuso-orbitaria / Adjunctive treatment with hyperbaric oxygen in a patient with rhino-sinuso-orbital mucormycosis

Se presenta un paciente, diabético insulino-dependiente, portador de una mucormicosis rino-sinuso-orbitaria, que habiendo sido tratado con debridamiento quirúrgico en dos oportunidades y anfotericina B en una dosis totald e 2900 mg, mantenía signos clínicos y tomográficos de actividad infecciosa con persistencia del hongo en a lesión. Se realizó debridamiento amplio con técnica microquirúrgica, se incrementó la dosis de anfotericina B hasta 3900 mg agregándose terapéutica adyuvante con oxígenio hiperbárico. El resultado fue exitoso, sin evidencias de recaída en 16 meses de seguimiento. Esta observación confirma la utilidad del oxígeno hiperbárico como terapéutica adyuvante en mucormicosis (AU)

Tratamiento adyuvante con oxigeno hiperbarico en un paciente con mucormicosis rino-sinuso-orbitaria / Adjunctive treatment with hyperbaric oxygen in a patient with rhino-sinuso-orbital mucormycosis

Se presenta un paciente, diabético insulino-dependiente, portador de una mucormicosis rino-sinuso-orbitaria, que habiendo sido tratado con debridamiento quirúrgico en dos oportunidades y anfotericina B en una dosis totald e 2900 mg, mantenía signos clínicos y tomográficos de actividad infecciosa con persistencia del hongo en a lesión. Se realizó debridamiento amplio con técnica microquirúrgica, se incrementó la dosis de anfotericina B hasta 3900 mg agregándose terapéutica adyuvante con oxígenio hiperbárico. El resultado fue exitoso, sin evidencias de recaída en 16 meses de seguimiento. Esta observación confirma la utilidad del oxígeno hiperbárico como terapéutica adyuvante en mucormicosis